HMNC Brain Health raised $50 million in a Series B round to advance two psychiatry programs into mid-stage studies. Medice led the financing, with additional support from other backers, positioning the company to continue clinical development for its depression pipeline. The capital injection underscores continued private-market investment in novel depression mechanisms as developers seek differentiation beyond established antidepressant classes. For a mid-stage psychiatry company, the funding is directly tied to trial execution timelines—patient recruitment, study monitoring, and manufacturing for investigational supplies. Market participants will watch how HMNC prioritizes which program advances first and how efficacy and tolerability signals emerge at the next readouts.